G

ood morning, everyone, and welcome to another working week. We hope the weekend — which was a protracted affair for many on this side of the pond — was relaxing and invigorating, because the treadmill has started up again. We could tell as our short person scrambled to leave for the local schoolhouse. As for us, yes, we are quaffing cups of stimulation and invite you to join us. Remember, no prescription is required. And of course, here are some tidbits to help you along. Hope your day is delightful and, as always, to do keep in touch …

The U.S. Supreme Court hears arguments on Monday about whether to halt a system that lets companies ask the U.S. Patent and Trademark Office to challenge patents rather than relying only on courts, Bloomberg News reminds us. Inter partes reviews are designed to be a low-cost alternative to lawsuits, but drug makers complain this uses a different legal standard than courts and is more likely to cancel a patent, depriving them of the right to a jury trial.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.